Etropal AD (XBUL:ETR) ROCE %: 5.39% (As of Dec. 2025)


XBUL:ETR Etropal AD XBUL:ETR
50 GF Score
Price €2.52
GF Value €8.55
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Etropal AD ROCE %?

Etropal AD XBUL:ETR 50 ROCE % is 5.39% as of Dec. 2025. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.55 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Etropal AD's annualized ROCE % for the quarter that ended in Dec. 2025 was 5.39%.

Etropal AD  (XBUL:ETR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Etropal AD ROCE % Related Terms

Etropal AD ROCE % Historical Data

* Premium members only.

The historical data trend for Etropal AD's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Etropal AD ROCE % Chart

Etropal AD Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.70 -4.64 2.31 3.88 5.39

Etropal AD Semi-Annual Data
Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.70 -4.64 2.31 3.88 5.39
XBUL:ETR
50GF Score
Etropal AD XBUL:ETR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Etropal AD ROCE % Calculation

Etropal AD's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.244/( ( (9.319 - 4.721) + (9.87 - 5.413) )/ 2 )
=0.244/( (4.598+4.457)/ 2 )
=0.244/4.5275
=5.39 %

Etropal AD's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=0.244/( ( (9.319 - 4.721) + (9.87 - 5.413) )/ 2 )
=0.244/( ( 4.598 + 4.457 )/ 2 )
=0.244/4.5275
=5.39 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.39% mean?
Etropal AD (XBUL:ETR) has a ROCE % of 5.39% as of Dec. 2025.
Is Etropal AD's ROCE % too high?
Etropal AD's current ROCE % is 5.39%. The Medical Devices & Instruments industry median ROCE % is 2.23. Etropal AD's value of 5.39% is 141.7% above this industry median. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's ROCE % compare to ISRG and BDX?
Etropal AD's ROCE % of 5.39% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Etropal AD's value of 5.39% is 141.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current ROCE % of 5.39% is 141.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current ROCE % is 5.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.55, compared to a current price of €2.52 — trading 70.5% below its estimated fair value. The current ROCE % is 5.39% and 141.7% above the Medical Devices & Instruments industry median of 2.23. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current ROCE % is 5.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Etropal AD (XBUL:ETR) Overvalued in 2026?

Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued. The current stock price of €2.52 is trading 70.5% below its estimated GF Value™ of €8.55. GuruFocus considers Etropal AD to be Significantly Undervalued.

Key valuation signals for XBUL:ETR:

  • ROCE %: 5.39%
  • GF Value™: €8.55 vs. price of €2.52 (70.5% below fair value)
  • GF Score™: 50/100 with 3 warning signs
  • Industry Position: 141.7% above the Medical Devices & Instruments median

No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Etropal AD Business Description

Address 191 Rusky Boulevard, Etropole, Sofia, BGR, 2180
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score

Get the complete analysis for XBUL:ETR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€8.55
GF Value